ERA Consulting has been acquired by PharmaLex Group, a leading provider of specialised services for the global life sciences sector.
ERA was founded in 1987 and has evolved into an international consulting firm that provides strategic product development and regulatory support. It and specialises in the development of vaccines, ATMPs and cell and gene therapies.
The firm has offices in Germany, the UK and Australia. It has an established multidisciplinary team of over 20 experts and key opinion leaders in the fields of molecular and cell biology, protein biochemistry, immunology, ATMPs, cell and gene therapy, non-clinical toxicology, manufacture, quality control, validation, and electronic submissions.
PharmaLex said the acquisition will enhance its capabilities and expertise but also expand its global geographical footprint and market reach, with a new location in Australia.
"Australia is considered one of the strategic hubs for early clinical trials for biotechnology companies and is therefore a perfect location for a future expansion to Asia Pacific region," it said in a statement.
“The ERA team is excited about being part of the PharmaLex Group, as this enables us to provide additional support to our clients through the breadth of PharmaLex’s services”, explained Andrew Moore, ERA chief operating officer.
“The addition of ERA to the PharmaLex Group represents a key milestone in the company’s strategic orientation as solution provider for the biotech sector. ERA’s extensive expertise will add significant value to further build our biopharma solutions,” said PharmaLex CEO Dr Thomas Dobmeyer.
“Expanding our global network into Australia is also an important step and will help us strengthen our Asia-Pacific reach," he added.